Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 5.92
- Piotroski Score 6.00
- Grade Hold
- Symbol (BMRN)
- Company BioMarin Pharmaceutical Inc.
- Price $63.45
- Changes Percentage (1.41%)
- Change $0.89
- Day Low $61.41
- Day High $63.76
- Year High $99.56
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/20/2025
- Fiscal Year End N/A
- Average Stock Price Target $107.50
- High Stock Price Target $135.00
- Low Stock Price Target $65.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $1.06
- Trailing P/E Ratio 76.12
- Forward P/E Ratio 76.12
- P/E Growth 76.12
- Net Income $167.65 M
Income Statement
Quarterly
Annual
Latest News of BMRN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
BioMarin Pharmaceutical Inc. (BMRN): Among the Best Genomics Stocks to Buy Right Now
The article discusses the growing importance of genomics stocks in the market, highlighting BioMarin Pharmaceutical Inc. and the potential of the genomics industry. Cathie Wood emphasizes the revoluti...
By Yahoo! Finance | 1 day ago -
Beyond the Balance Sheet: What SWOT Reveals About Biomarin Pharmaceutical Inc (BMRN)
Biomarin Pharmaceutical Inc shows financial growth in its 10-Q report, with a focus on rare-disease therapies. Despite revenue increase, rising operating expenses require careful management. Market le...
By Yahoo! Finance | 2 weeks ago -
Biomarin Pharmaceutical Inc (BMRN) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...
BMN 333 aims to enhance CNP's half-life for improved effects in skeletal disorders. The trial length and expansion into other indications are flexible based on data. Factors impacting financials inclu...
By Yahoo! Finance | 3 weeks ago
